Company: DVAX
Filing Date: 2025-02-20
Form Type: DEFA14A
Source: 0001193125-25-029819
Chunk: 4

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-02-20
Form: DEFA14A
Chunk 4
---
kman, and that Deep Track must have the opportunity to gain majority 
 “control” of the Board by 2026. Dynavax’s Board was told that independent candidates proposed by the Board “don’t count” toward Deep Track’s demand for control.                                                               |

Page 2 of 5

| • |     | Notwithstanding Mr. Kroin’s alarming focus on gaining control of the Board by 2026 without paying other                                                                                                                                     
 stockholders a control premium, the Board revised its settlement proposal to include the appointment of a third mutually agreed independent candidate and three current directors retiring by the 2026 Annual Meeting. Deep Track summarily 
 rejected this proposal, steadfast in its insistence that it have the opportunity to take control of the Board by 2026.                                                                                                                      |

While the Board believes this proxy contest is unreasonable and disregards multiple constructive settlement offers by the Board, Dynavax remains committed to constructive and reasonable engagement with Deep Track, while ensuring that the best interests of all stockholders – not only those of Mr. Kroin and his fund – are protected and represented. The Board will review Deep Track’s materials and, if appropriate, present its formal recommendation regarding director nominations in its proxy statement, which will be filed with the U.S. Securities and Exchange Commission and mailed to all stockholders eligible to vote at the 2025 Annual Meeting, which has not yet been scheduled. Dynavax stockholders are not required to take any action at this time. Goldman Sachs & Co. LLC is serving as financial advisor to Dynavax and Cooley LLP is serving as legal counsel. WHAT IS HEPLISAV-B? HEPLISAV-Bis a shot given to adults 18 years of age and older to help prevent infection caused by the hepatitis B virus. HEPLISAV-Bis usually given in the arm muscle. HEPLISAV-Bis given in 2 doses, 1 month apart, by a healthcare provider. IMPORTANT SAFETY INFORMATION If you have a history of severe allergic reaction after a previous dose of any hepatitis B vaccine, or to any ingredient of HEPLISAV-B,including yeast, do not take HEPLISAV-B. HEPLISAV-Bmust be given by a medical professional, who will monitor you afterwards, to check for allergic reaction. If you are immunocompromised, or receiving immunosuppressant therapy, you may have less of an immune response to HEPLISAV-B. Some people have hepatitis B infection without being aware of it or showing any symptoms. If